ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics onInternational journal of molecular sciences · 2019Pooled it
- Role of isoflavones in multiple sclerosis.IBRO neuroscience reports · 2025Review
- Genome-wide identification of the WRKY transcription factors family and regulation of metabolites under cold stress in Astragalus membranaceus.BMC plant biology · 2025Article
- Microwave-assisted one-step synthesis of polyacrylamide/NiO nanocomposite for biomedical applications.RSC advances · 2025Article
- Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein.International journal of molecular sciences · 2024Article
- Potential Therapeutic Targets of Formononetin, a Type of Methoxylated Isoflavone, and Its Role in Cancer Therapy through the Modulation of Signal Transduction Pathways.International journal of molecular sciences · 2023Review
- A review of the botany, phytochemistry, traditional uses, pharmacology, toxicology, and quality control of theFrontiers in pharmacology · 2023Review
- Parent-Metabolite Pharmacokinetic Modeling of Formononetin and Its Active Metabolites in Rats after Oral Administration of Formononetin Formulations.Pharmaceutics · 2022Article
- Solamargine Inhibits the Development of Hypopharyngeal Squamous Cell Carcinoma by Decreasing LncRNAFrontiers in pharmacology · 2022Article
- Potential Mechanisms of Plant-Derived Natural Products in the Treatment of Cervical Cancer.Biomolecules · 2021Review
- Astragalus-Containing Chinese Herbal Medicine Combined With Chemotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2021Article
- Exploring the In Vivo Existence Forms (23 Original Constituents and 147 Metabolites) of Astragali Radix Total Flavonoids and Their Distributions in Rats Using HPLC-DAD-ESI-IT-TOF-MSMolecules (Basel, Switzerland) · 2020Article
- Inhibitory effects of formononetin on the monocrotaline‑induced pulmonary arterial hypertension in rats.Molecular medicine reports · 2020Article
- Article
- Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.Molecular medicine reports · 2019Article
- Article
- Formononetin Upregulates Nrf2/HO-1 Signaling and Prevents Oxidative Stress, Inflammation, and Kidney Injury in Methotrexate-Induced Rats.Antioxidants (Basel, Switzerland) · 2019Article
- Effects and significance of formononetin on expression levels of HIF-1α and VEGF in mouse cervical cancer tissue.Oncology letters · 2019Article
- Review
- Formononetin: A Review of Its Anticancer Potentials and Mechanisms.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, cervical cancer (CC) is the third most common malignancy in women, and it remains a leading cause of cancer-related death of women. Genomic studies indicate that phosphoinositide 3-kinase (PI3K)/AKT signaling is one of the most frequently deregulated pathways in several human cancers, including CC. This signaling pathway has an important role in cancer cell proliferation, survival, motility, and metabolism, and therefore could be an attractive therapeutic target. In a previous study, we used a sensitive and high-speed homogeneous assay for the detection of kinase activity and for screening of PI3K/AKT signaling inhibitors in a high-throughput screening (HTS) format and then obtain formononetin, as an O-methylated isoflavone existed in a number of plants and herbs like Astragalus membranaceus. We showed that formononetin inhibited the phosphorylation of AKT and induced the apoptosis of CC cell line HeLa in a dose-dependent manner. Furthermore, formononetin suppressed xenograft tumor growth in nude mice. Our results indicated that formononetin may be used as an anti-cancer drug for cervical cancer in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.